Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 December 2020
Prof Abdon Atangana
Prof Abdon Atangana is known for his work in developing a new fractional operator used to model real-world problems arising in the fields of science, technology, and engineering. He was recently awarded the TWAS Mohammad A. Hamdan Award by The World Academy of Sciences.

Prof Abdon Atangana, Professor of Applied Mathematics in the Institute for Groundwater Studies at the University of the Free State (UFS), was awarded the TWAS Mohammad A. Hamdan Award by The World Academy of Sciences for the advancement of science in developing countries.

It is the first time that the TWAS Mohammad A. Hamdan Award was bestowed. According to a statement issued by TWAS, this award is given for outstanding mathematical work carried out by a scientist working and living in Africa or the Arab region. It states that the award can be given for work in pure mathematics, applied mathematics, probability, or statistics. Prof Atangana received the award for his contribution to fractal mathematics and partial differential equations.

Making a difference in society

He is known for his research in developing a new fractional operator, the Atangana-Baleanu operator, which is used to model real-world problems. With this operator, he not only describes the rate at which something will change, but also account for disrupting factors that will help to produce better projections.

His work can be applied to make complicated predictions in the fields of science, technology, and engineering. His models can, for instance, help to predict the spread of infectious diseases among people in a settlement, forecasting the number of people who will be infected each day, the number of people who will recover, and the number of people who will die.

Prof Atangana’s models can also help to advise people drilling for water by predicting how groundwater is flowing in a complex geological formation. These are only two examples of how his work can be applied to make a difference in society.

The award from TWAS is the third prestigious commendation he has received in the past month. He was recently named as one of the top 1% scientists on the global Clarivate Web of Science list. His name also appeared on a global list of leading scientists published by Stanford University in the United States. The list is the result of a study published in PLOS Biology, a peer-reviewed open-access journal.

World’s most accomplished scientists

Honours awarded by TWAS and its partners are among the most prestigious for research in the developing world. They recognise outstanding achievements and contributions to science and acknowledge the best work by scientists from the global South.

TWAS, founded in 1983 by a group of scientists under the leadership of Pakistani physicist and Nobel laureate, Abdus Salam, believes that developing nations – by growing strength in science and engineering – will be able to address challenges such as hunger, disease, and poverty, through their knowledge and skills.

TWAS is represented in 100 countries, and of the more than a thousand elected fellows, 14 are Nobel laureates. Eighty-four percent of these fellows are from developing nations. TWAS fellows are also some of the world’s most accomplished scientists.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept